A new oral antibiotic, gepotidacin, was approved by the Food and Drug Administration (FDA) this week for the treatment of uncomplicated urinary tract infections (UTIs). According to the manufacturer, GSK plc, gepotidacin is a first-in-class antibiotic with a novel mechanism that inhibits bacterial DNA replication to treat female adults and pediatric patients (≥12 years, ≥40 kg) with uncomplicated UTIs. It’s designed to target several of the most common UTI-causing bacteria such as E. coli and …
Read More